Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
7
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
7
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
7
×
texas blog main
texas top stories
7
×
wisconsin blog main
wisconsin top stories
boston top stories
cancer
alzheimer's disease
cancer immunotherapy
clinical trials
deals
eli lilly
merck
astrazeneca
biogen
fda
gilead sciences
What
bio
roundup
drug
acquisitions
ceo
companies
week
biggest
daniel
debut
gilead
moves
nash
news
o’day
sciences
albert
alzheimer’s
announced
annual
approval
approved
assessed
attention
biogen’s
biopharmaceutical
biotech
black
bourla
build
buy
collabs
communities
company
company’s
conference
continue
convo
covid
crispr
Language
unset
unknown
Current search:
startups
×
abbvie
×
" texas top stories "
×
" new york top stories "
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More